XTL Biopharmaceuticals Ltd. (XTLB) and CohBar Inc. (NASDAQ:CWBR) Comparing side by side

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) and CohBar Inc. (NASDAQ:CWBR) are two firms in the Biotechnology that compete against each other. Below is a comparison of their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
XTL Biopharmaceuticals Ltd. 1 0.00 3.49M 1.16 1.69
CohBar Inc. 2 0.00 27.69M -0.36 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of XTL Biopharmaceuticals Ltd. and CohBar Inc.

Profitability

Table 2 has XTL Biopharmaceuticals Ltd. and CohBar Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
XTL Biopharmaceuticals Ltd. 249,695,929.03% 70.3% 68.6%
CohBar Inc. 1,548,138,208.65% -76% -62.3%

Risk & Volatility

XTL Biopharmaceuticals Ltd. is 7.00% more volatile than Standard & Poor’s 500 due to its 1.07 beta. CohBar Inc.’s 14.00% more volatile than Standard & Poor’s 500 volatility due to the company’s 1.14 beta.

Liquidity

XTL Biopharmaceuticals Ltd.’s Current Ratio is 51.1 while its Quick Ratio is 51.1. On the competitive side is, CohBar Inc. which has a 15.5 Current Ratio and a 15.5 Quick Ratio. XTL Biopharmaceuticals Ltd. is better positioned to pay off short and long-term obligations compared to CohBar Inc.

Insider and Institutional Ownership

Roughly 11.6% of XTL Biopharmaceuticals Ltd. shares are held by institutional investors while 9.5% of CohBar Inc. are owned by institutional investors. XTL Biopharmaceuticals Ltd.’s share held by insiders are 1%. On the other hand, insiders held about 32.85% of CohBar Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
XTL Biopharmaceuticals Ltd. -0.88% -15.78% -17.6% -13.17% 26.59% 13.43%
CohBar Inc. 13.79% -5.71% -40.43% -48.6% -70.27% -46.95%

For the past year XTL Biopharmaceuticals Ltd. has 13.43% stronger performance while CohBar Inc. has -46.95% weaker performance.

Summary

XTL Biopharmaceuticals Ltd. beats CohBar Inc. on 6 of the 10 factors.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and SjogrenÂ’s syndrome. The company also develops recombinant human erythropoietin for the treatment of multiple myeloma patients. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Raanana, Israel.

CohBar, Inc., a biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. Its lead MBT drug candidates include CB4209 and CB4211, which are in IND-enabling studies for the treatment of fatty liver disease, non-alcoholic steatohepatitis, obesity, and type 2 diabetes mellitus. The company is also developing Humanin, a mitochondrial-derived peptide to treat AlzheimerÂ’s disease, atherosclerosis, myocardial and cerebral ischemia, and type 2 diabetes mellitus; SHLP-6 for the treatment of cancer; and SHLP-2 to treat AlzheimerÂ’s disease and type 2 diabetes mellitus. CohBar, Inc. was founded in 2007 and is headquartered in Menlo Park, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.